Who are you looking for?

Install Famoose

Keep Famoose on your home screen or desktop for easy access.

Open this site in Chrome or Edge and look for Install app in the browser menu or address bar. If no install option appears, you can bookmark Famoose instead.

Famoose.co
Appearance
Text size
Page width
Colour
Contents
Ebola vaccine trials and deployment

Ebola vaccine trials and deployment

Ring-vaccination trials and emergency use helped turn an Ebola vaccine candidate into an approved outbreak-control tool.

When
2015–2019
Where
Guinea and later Ebola outbreak settings
An electron micrograph of Ebola virus; it depicts the pathogen, not a vaccine product.
An electron micrograph of Ebola virus; it depicts the pathogen, not a vaccine product.

Ring-vaccination trials and emergency use helped turn an Ebola vaccine candidate into an approved outbreak-control tool.

01

Background

Research accelerated by catastrophe

The West African Ebola epidemic exposed the absence of widely available vaccines and effective treatment options. Candidates developed through earlier research were moved rapidly into testing. Communities experiencing the outbreak, local health workers and international teams all contributed to the process.[1]

02

What happened

  1. 2015

    A ring-vaccination trial in Guinea

    Researchers vaccinated contacts and contacts of contacts around identified cases. The design tested an outbreak-control strategy as well as the product. Analysis focused on disease occurring at least ten days after vaccination, allowing time for protection to develop; omitting that window would misrepresent the findings.[2]

  2. 2019

    Toward approved use

    Further outbreak deployment and regulatory assessment led to major approval and prequalification milestones in 2019. These steps supported procurement and country use beyond an experimental trial. Surveillance, community trust and rapid identification of contacts remained necessary alongside vaccination.[3]

03

Impact & evidence

Strong trial protection

Results with a defined scope

The final trial reported high protection from the rVSV-ZEBOV vaccine within the study conditions. That evidence should not be turned into a claim of universal protection against every Ebola virus species or instantaneous immunity after an injection.[2]

04

Aftermath & legacy

A tool within a wider response

Vaccination strengthened Ebola control but did not replace clinical care, infection prevention or dignified, safe burial practices. The achievement combined biomedical research with difficult fieldwork and the participation of people living through an epidemic.[1]

Sources & image credits (3)
  1. Wikipedia — Ebola vaccine ↗
  2. WHO: final Guinea trial results, 2016 ↗
  3. WHO: regulatory milestone for the Ebola vaccine, 2019 ↗

CDC/ Dr. Frederick A. Murphy Image source ↗

Related historical cases

Diagram of the penicillin core structure; a modern scientific illustration.Scientific milestone

The discovery and development of penicillin

Turning an observation about mould into a treatment for bacterial infection.

A child receiving oral polio vaccine in a later immunisation campaign, not the injected Salk vaccine of 1955.Scientific milestone

The first polio vaccine rollout

Bringing an effective vaccine against paralytic polio into widespread use.

A smallpox vaccination kit with vaccine vial and bifurcated needle.Public-health milestone

The eradication of smallpox

Eliminating a human infectious disease through an international public-health campaign.

An illustrative photograph of oral rehydration solution.Public-health milestone

The spread of oral rehydration therapy

Making lifesaving rehydration more accessible during diarrhoeal illness.

The Silent Highwayman, a contemporary Punch cartoon about the polluted Thames.Public-health milestone

London's sewer revolution

Turning a sanitation crisis into a major urban sewer-building programme.